Comparing Bladder Medication Effects on Thinking, Urinary Symptoms, and Daily Function in Older Women with Urgency Incontinence

What this Trial Is About

Researchers are evaluating the effects of different bladder treatments on cognitive, urinary, and other aging-related functions in ambulatory older women who have urgency-predominant urinary incontinence and normal or mildly impaired cognitive function. This randomized, double-blinded, three-arm study compares anticholinergic bladder therapy, beta-3-adrenergic agonist bladder therapy, and no bladder pharmacotherapy. The study aims to understand how these treatments affect memory, urinary symptoms, and physical abilities over time. Participants are assigned to one of three groups one receiving tolterodine tartrate an anticholinergic medication, another receiving mirabegron a beta-3-adrenergic agonist, and a placebo group receiving microcrystalline cellulose capsules. All groups receive behavioral self-management education including written materials about timed urination, lifestyle changes, pelvic floor exercises, and urge suppression. Treatment lasts 6 months, with follow-up assessments continuing up to 9 months to monitor lasting effects. During the study, participants will undergo various cognitive tests, urinary symptom tracking, physical performance assessments, and questionnaires on sleep quality, mood, and bowel symptoms at baseline, 6 months, and 9 months. Researchers will closely monitor changes in cognitive function, urinary incontinence episodes, physical abilities, and quality of life. The study includes safety monitoring and aims to gather comprehensive data on how these bladder treatments impact older womens overall mental and physical health over time.

TReating Incontinence for Underlying Mental and Physical Health